WS Xu, RB Parmigiani, PA Marks - Oncogene, 2007 - nature.com
This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors (HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …
PA Marks, WS Xu - Journal of cellular biochemistry, 2009 - Wiley Online Library
The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic targets for cancer, neurodegenerative diseases and a number of other disorders is an area …
K Keller, M Jung - Epigenetic Therapy of Cancer: Preclinical Models and …, 2013 - Springer
Histone deacetylases are key enzymes of epigenetic regulation and are therefore involved in crucial cellular events like transcription, differentiation, apoptosis and cell division. The …
L Li, R Bhatia - Clinical cancer research, 2011 - AACR
Adult stem cells are maintained in a quiescent state but are able to exit quiescence and rapidly expand and differentiate in response to stress. The quiescent state appears to be …
PW Laird - Human molecular genetics, 2005 - academic.oup.com
The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our understanding of chromatin structure, histone modification, transcriptional activity and DNA …
A Nebbioso, V Carafa, R Benedetti, L Altucci - Molecular oncology, 2012 - Elsevier
Epigenetic inactivation of pivotal genes involved in correct cell growth is a hallmark of human pathologies, in particular cancer. These epigenetic mechanisms, including crosstalk …
PA Marks - Expert opinion on investigational drugs, 2010 - Taylor & Francis
Importance of the field: Histone deacetylase (HDAC) inhibitors are being developed as a new, targeted class of anticancer drugs. Area covered in this review: This review focuses on …
MMHJ Van Gelder, IALM Van Rooij… - Human reproduction …, 2010 - academic.oup.com
BACKGROUND Although prescription drug use is common during pregnancy, the human teratogenic risks are undetermined for more than 90% of drug treatments approved in the …
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer cell, 2010 - cell.com
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …